MHRA and Malaysia strengthen partnership on healthcare innovation and research
The UK’s MHRA and Malaysia’s health ministry agreed to deepen cooperation on medicines, devices, and clinical trials during talks in Kuala Lumpur, aiming to share expertise and streamline approvals while upholding safety standards.
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) reaffirmed its commitment to strengthening regulatory ties with Malaysia during high-level discussions in Kuala Lumpur. MHRA Chief Executive Lawrence Tallon joined Malaysian Minister YB Datuk Seri Dr Dzulkefly Ahmad to review progress in healthcare, medicines regulation, and research. The meeting highlighted Malaysia’s ambition to become a regional leader in healthcare innovation, clinical research, and life sciences.
Both sides explored opportunities to deepen collaboration in medicines, medical devices, and clinical trials, focusing on expert exchanges and regulatory knowledge sharing. Discussions also covered advancing work on emerging technologies and identifying more efficient development and approval pathways. The talks emphasized maintaining high standards of safety, quality, and effectiveness throughout any joint initiatives.
A series of practical next steps were agreed to advance the partnership, including further engagement between experts and joint working opportunities for teams. These steps aim to translate policy discussions into actionable regulatory cooperation. The meeting reflects the MHRA’s broader strategy to strengthen partnerships across the ASEAN region.
The collaboration is part of the MHRA’s wider effort to support innovation that delivers benefits for patients globally. By aligning regulatory practices, both agencies seek to enhance the development and approval of safe, effective medical products. The partnership underscores the shared commitment to advancing healthcare standards through international cooperation.